Lucanthone, a Potential PPT1 inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation and Slows the Growth of Temozolomide-Resistant Gliomas in Vivo” by Daniel Radin, Sophie Shifman, Ian Outhwaite, Aryan Sharma, Robert Bases, Markus Seeliger, and Stella Tsirka

Journal of Pharmacology and Experimental Therapeutics / JPET-AR-2023-002021

Figure S1. PPT1 correlates in gliomas. (A) Survival of LGG and GBM patients stratified by median expression of PPT1. (B) PPT1 expression across various grades of glioma. ANOVA p<0.0001. ***p<0.001, ****p<0.0001 Tukey test compared to expression in oligodendroglioma. ++++p<0.0001, Tukey test compared to expression in oligoastrocytoma. &&&&p<0.0001, Tukey test compared to expression in astrocytoma. (C) PPT1 expression in normal tissue vs expression in GBM subtypes. ANOVA p=0.0006. *p<0.05, **p<0.01, ***p<0.001, Dunnett’s multiple comparison test to expression in normal tissue. (D) Anatomical distribution of PPT1 in various GBM tumor areas. ANOVA p=0.44, indicating similar expression. (E) Lucanthone does not alter PPT1 mRNA expression in GL261 tumors but decreases Olig2 mRNA. Mean +/- SEM is depicted, N=6 animals per group. P=0.38, ***p<0.001, t-test.